Dalton-Fitzgerald Eimile, Tiro Jasmin, Kandunoori Pragathi, Halm Ethan A, Yopp Adam, Singal Amit G
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Internal Medicine, Parkland Health Hospital System, Dallas, Texas.
Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas; Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas.
Clin Gastroenterol Hepatol. 2015 Apr;13(4):791-8.e1. doi: 10.1016/j.cgh.2014.06.031. Epub 2014 Jul 11.
BACKGROUND & AIMS: Fewer than 20% of patients with cirrhosis undergo surveillance for hepatocellular carcinoma (HCC), therefore these tumors often are detected at late stages. Although primary care providers (PCPs) care for 60% of patients with cirrhosis in the United States, little is known about their practice patterns for HCC surveillance. We investigated factors associated with adherence to guidelines for HCC surveillance by PCPs.
We conducted a web-based survey of all 131 PCPs at a large urban hospital. The survey was derived from validated surveys and pretested among providers; it included questions about provider and practice characteristics, self-reported rates of surveillance, surveillance test and frequency preference, and attitudes and barriers to HCC surveillance.
We obtained a clinic-level response rate of 100% and a provider-level response rate of 60%. Only 65% of respondents reported annual surveillance and 15% reported biannual surveillance of patients for HCC. Barriers to HCC surveillance included not being up-to-date with HCC guidelines (68% of PCPs), difficulties in communicating effectively with patients about HCC surveillance (56%), and more important issues to manage in the clinic (52%). Approximately half of PCPs (52%) reported using ultrasound or measurements of α-fetoprotein in surveillance; 96% said that this combination was effective in reducing HCC-related mortality. However, many providers incorrectly believed that clinical examination (45%) or levels of liver enzymes (59%) or α-fetoprotein alone (89%) were effective surveillance tools.
PCPs have misconceptions about tests to detect HCC that contribute to ineffective surveillance. Reported barriers to surveillance include suboptimal knowledge about guidelines, indicating a need for interventions, including provider education, to increase HCC surveillance effectiveness.
肝硬化患者中接受肝细胞癌(HCC)监测的比例不到20%,因此这些肿瘤往往在晚期才被发现。尽管在美国,初级保健提供者(PCP)照顾着60%的肝硬化患者,但对于他们进行HCC监测的实践模式却知之甚少。我们调查了与PCP遵循HCC监测指南相关的因素。
我们对一家大型城市医院的所有131名PCP进行了基于网络的调查。该调查源自经过验证的调查问卷,并在提供者中进行了预测试;它包括有关提供者和实践特征、自我报告的监测率、监测测试和频率偏好以及对HCC监测的态度和障碍等问题。
我们获得了100%的诊所层面回复率和60%的提供者层面回复率。只有65%的受访者报告对患者进行年度监测,15%报告进行半年一次的HCC监测。HCC监测的障碍包括不了解最新的HCC指南(68%的PCP)、难以与患者就HCC监测进行有效沟通(56%)以及诊所中有更重要的问题需要处理(52%)。大约一半的PCP(52%)报告在监测中使用超声或甲胎蛋白测量;96%的人表示这种组合在降低HCC相关死亡率方面有效。然而,许多提供者错误地认为临床检查(占45%)、单独的肝酶水平(占59%)或单独的甲胎蛋白水平(占89%)是有效的监测工具。
PCP对检测HCC的测试存在误解,这导致监测无效。报告的监测障碍包括对指南的了解不足,这表明需要采取干预措施,包括对提供者进行教育,以提高HCC监测的有效性。